Clinical review

BMJ

Volumn 325, Issue 7368, 2002, Pages 822-

  Sanderson, R J ^a   Ironside, J A D ^a   Wei, William I ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007728248     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.325.7368.822     Document Type: Article

References (33)

1. Quinn M. Cancer trends in England and Wales 1950–1999. London: Stationery Office, 2001. (Studies on medical and population subjects No 66.)
2. Scottish Cancer Intelligence Unit. Trends in cancer survival in Scotland 1971–1995. Edinburgh: Information and statistics division, SCIU: 2000.
3. van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, et al. Frequent loss of chromosome 9p21–22 early in head and neck cancer progression. Cancer Res 1994; 54: 1156–1158.
4. Merino OR, Lindberg RD, Fletcher GH. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1977; 40: 145–151.
5. Panosetti E, Luboinski B, Marmelle G, Richard JM. Multiple synchronous and metachronous cancers of the upper autodigestive tract: a nine-year study. Laryngoscope 1989; 99: 1267–1273.
6. Department of Health. Referral guidelines for suspected cancer. London: DoH, 2000: 29. www.doh.gov.uk/pub/docs/doh/guidelines.pdf (accessed 20 Aug 2002).
7. McGuirt WF, McCabe BF. Significance of node biopsy before definitive treatment of cervical metastatic carcinoma. Laryngoscope 1978; 88: 594–597.
8. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane Database Syst Rev 2002;(1):CD001829.
9. International Union against Cancer. Classification of malignant tumours. 5th ed. In: New York: Wiley-Liss, 1997. Sobin LH, Wittekind C, eds.
10. British Association of Otorhinolaryngologists Head and Neck Surgeons. Effective head and neck cancer management. London: BAOHNS, 2000. www.baoms.org.uk/download/cancer/baorl-hns/hnc.pdf (accessed 20 Aug 2002).
11. Northrop MF, Fletcher GH, Jesse RH, Lindberg RP. Evolution of neck disease in patients with primary squamous cell carcinoma of the oral tongue, floor of mouth and palatine arch and clinically positive neck nodes neither fixed nor bilateral. Cancer 1972; 29: 23–30.
12. Steiner W. Results of curative laser microsurgery of laryngeal carcinoma. Am J Otolaryngol 1993; 14: 116–121.
13. Steiner W, Ambrosch P, Hess CF, Kron M. Organ preservation by trans-oral laser microsurgery in piriform fossa carcinoma. Otolaryngol Head Neck Surg 2001; 124: 58–67.
14. Department of Veteran Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–1690.
15. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890–899.
16. Newkirk KA, Cullen KJ, Harter KW, Picken CA, Sessions RB, Davidson BJ. Planned neck dissection for advanced primary head and neck malignancy treated with organ preservation therapy: disease control and survival outcomes. Head Neck 2001; 23: 73–79.
17. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949–955.
18. Tobias JS, Monson KM, Gladholm J, et al. UKHAN 1: a prospective multi-centre randomised trial investigating chemotherapy as part of initial management in advanced head and neck cancer. Radiother Oncol 2001; 58(suppl 1): S16.
19. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L, Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with sub group analysis. Head Neck 2001; 23: 579–589.
20. Henk JM. Concomitant chemoradiation for head and neck cancer: saving lives or grays. Clin Oncol (R Coll Radiol) 2001; 13: 333–335.
21. Capizzi RL, Oster W. Chemoprotective and radioprotective effects of Amiphostine: an update of clinical trials. Int J Hematol 2000; 72: 425–435.
22. Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic I, Milicic B, Niklic N. Radiation therapy alone or with concurrent low dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomised trial. Radiother Oncol 1997; 43: 29–37.
23. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Bertelsen A, Specht L, et al. A randomised double-blind phase III study of nimorazole as a hypoxic radiosensitiser of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish head and neck cancer study (DAHANCA) protocol 5–85. Radiother Oncol 1998; 48: 344–346.
24. Thames HD Jr, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8: 219–226.
25. Nutting C, Dearnaley DP, Webb S. Intensity modulated radiotherapy: a clinical review. Br J Radiol 2000; 73: 459–469.
26. Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Boysen M, Evenson JF, Biorklund A, et al. A prospective study of quality of life in head and neck cancer patients. I: At diagnosis. Laryngoscope 2001; 111: 669–680.
27. Bjordal K, Ahlner-Elmqvist M, Hammerlid E, Boysen M, Evenson JF, Biorklund A, et al. A prospective study of quality of life in head and neck cancer patients. II. Longitudinal data. Laryngoscope 2001; 111: 1440–1452.
28. Caponigro F, Massa E, ManZione L, Rosati G, Biglietto M, De Lucia L, et al. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the southern Italy cooperative oncology group (SICOG). Ann Oncol 2001; 12: 199–202.
29. Khuri FR, Nemunaitis J, Ganly I, Arseneay J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.
30. Moore SR, Johnson NW, Pierce AM, Wilson DF. The epidemiology of mouth cancer: a review of global incidence. Oral Dis 2000; 6: 65–74.
31. Wunsch-Filho V, de Camargo EA. The burden of mouth cancer in Latin America and the Caribbean: epidemiologic issues. Semin Oncol 2001; 28: 158–168.
32. Wei WI. Management of early carcinoma of the larynx: the Asian perspective. ENT News 2000; 9: 18–19.
33. Qu JY, Yuen PW, Huang Z, Kwong D, Sham J, Lee SL, et al. Preliminary study of in vivo autofluorescence of nasopharyngeal carcinoma and normal tissue. Lasers Surg Med 2000; 26: 432–440.